Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 May 18;2(5):100284.
doi: 10.1016/j.xcrm.2021.100284.

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?

Jens Juul Holst  1
Affiliations
Comment

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?

Jens Juul Holst. Cell Rep Med. .

Abstract

Lu et al.1 previously demonstrated that antagonist antibodies against the GIP receptor promote weight loss combined with GLP-1. They now elegantly developed a conjugate of GIPR antibodies and GLP-1 and show effective weight loss in obese non-human primates.

PubMed Disclaimer

Conflict of interest statement

J.J.H. is a founder of Antag Therapeutics and a member of its scientific advisory board, a member of scientific advisory boards for NovoNordisk, and co-author of a patent regarding GIP antagonists.

Comment on

References

    1. Lu S.-C., Chen M., Atangan L., Killion E.A., Komorowski R., Cheng Y., Netirojjanakul C., Falsey J.R., Stolina M., Dwyer D. GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys. Cell Rep. Med. 2021;2 this issue, 100263-1–100263-17. - PMC - PubMed
    1. Müller T.D., Finan B., Bloom S.R., D’Alessio D., Drucker D.J., Flatt P.R., Fritsche A., Gribble F., Grill H.J., Habener J.F. Glucagon-like peptide 1 (GLP-1) Mol. Metab. 2019;30:72–130. - PMC - PubMed
    1. Wilding J.P.H., Batterham R.L., Calanna S., Davies M., Van Gaal L.F., Lingvay I., McGowan B.M., Rosenstock J., Tran M.T.D., Wadden T.A., STEP 1 Study Group Once-Weekly Semaglutide in Adults with Overweight or Obesity. N. Engl. J. Med. 2021;384:989. - PubMed
    1. Holst J.J., Rosenkilde M.M. GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists. J. Clin. Endocrinol. Metab. 2020;105:105. - PMC - PubMed
    1. Killion E.A., Wang J., Yie J., Shi S.D., Bates D., Min X., Komorowski R., Hager T., Deng L., Atangan L. Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models. Sci. Transl. Med. 2018;10:10. - PubMed

MeSH terms

Substances

LinkOut - more resources